Bryce James Visits Historic College Basketball Program This WeekAP Business SummaryBrief at 2:47 p.m. EST3 jili 。

Mississippi blows opportunity at making the College Football Playoff with Florida loss

The Miami Hurricanes, who once appeared to be a near-lock for the College Football Playoff, are not playing for a national title. Instead, they will play in the Pop-Tarts Bowl in Orlando. That bowl berth against Iowa State is a let-down for fans with dreams of a sixth national title in their minds, as well as players hoping to compete for a championship. However, Miami’s trip to Orlando and the lead-up to it are still crucial periods for the Hurricanes for multiple reasons. First, it’s a chance for the program to achieve something it has not done in more than two decades: win 11 games. Although the 11th win won’t get them closer to a championship, it is a good sign of the program’s progress over Mario Cristobal’s tenure. It would also end UM’s five-game losing streak in bowls. “We’re not satisfied,” Cristobal said. “We want to win every single game. We won 10. We were close on the other two, but close isn’t good enough. We want progress. We’re hungry and driven to get better, and so that’s what our focus is on: to improving as a football program, to getting better, to moving into the postseason with an opportunity against a great football team like this and putting our best on the field.” People are also reading... There are signs the Hurricanes will show up at close to full strength for the bowl game. Running back Damien Martinez announced he was going to play, and star quarterback Cam Ward said in a video call posted on social media that he intends to play, as well. “We’re trying to win our first bowl game in 20 years,” Ward said in the video, mistaking the length of UM’s long bowl losing streak. “We’re going hard.” Playing in the bowl game also provides the opportunity for the Hurricanes to get in several practices between now and the game. That means Miami can develop its young players and prepare them for next season during both the practices and the bowl game itself. “It’s extremely valuable,” Cristobal said. “You really don’t have many opportunities throughout the course of the year — time is limited more and more each season with your student-athletes. I want to state this and be very clear: it’s very important, it’s ultra-important for the University of Miami to continue to develop and grow and progress by stressing the importance of offseason opportunities ... You learn a lot about your team and learn a lot about your people and your program when you head to the postseason.” Of course, there are potential negatives. Players can get hurt; Mark Fletcher Jr. suffered a foot injury in the Pinstripe Bowl last year that cost him all of spring practice. A poor performance can also potentially set the tone for next season, like how Florida State, fresh off a playoff snub last year, suffered a devastating loss against Georgia in the Orange Bowl and went on to a dismal 2-10 season this year. “This is the ending of ’24 and the beginning of ’25,” Cristobal said. “This is the last opportunity to be on the field and carry some momentum into the offseason. So it is, in essence, it is the most important game because it’s the next game. “There’s a lot of excitement in the form of opportunity for our guys. Our guys love to play football. The chance to play one more time with this special group — this is a special group of guys now. They’ve worked hard to really change the trajectory of the University of Miami, and they want to continue to elevate the status and the culture at the University of Miami. So certainly a ton to play for.” ____ Be the first to know Get local news delivered to your inbox!BJP firm on Devendra Fadnavis as Maharashtra CM despite Eknath Shinde's resistance - The Times of India

LOS ANGELES — Top-ranked South Carolina felt something it hasn't known in over 2 1/2 years. The sting of defeat after being thoroughly dominated in a 77-62 loss to No. 5 UCLA on Sunday. Gone was the overall 43-game winning streak. Done was the run of 33 consecutive road victories. And the No. 1 ranking it's held for 23 consecutive polls will disappear Monday. "This is what we usually do to teams," coach Dawn Staley said. "We were on the receiving end of it." South Carolina hadn't lost since April 2023, when Caitlin Clark and Iowa beat the Gamecocks in the national semifinals of the NCAA Tournament. The Bruins (5-0) shot 47% from the floor and 3-point range, hit 11 of 14 free throws and had five players in double figures. "They actually executed our game plan to a T," Staley said. The Gamecocks (5-1) were held to 36% shooting, had just two players in double figures and neither was leading scorer Chloe Kitts, who was held to 2 points on 1 of 7 shooting. They never led, got beat on the boards, 41-34, and were outscored 26-18 in the paint and 8-1 in fast break points. They only made eight trips to the free throw line. "Our kids fought," Staley said, "but we ran into a buzzsaw." South Carolina did manage to limit 6-foot-7 UCLA star Lauren Betts, who had 11 points and 14 rebounds, despite no longer having a dominant center of their own. The Bruins responded by getting the ball to others and eight of their 10 players scored. "We did an excellent job on Betts and we got killed by everyone else," Staley said. Tessa Johnson was the only other Gamecock in double figures with 14. "We needed a lot more than Tessa today," Staley said. The Gamecocks never got their offense in gear, starting the game 0 for 9 before trailing 20-10 at the end of the first quarter. They were down 43-22 at halftime. "Our shot selection is something we're dealing with on a daily basis," Staley said. The Gamecocks outscored UCLA 40-34 in the second half, but the Bruins' big early lead easily held up. "Beautiful basketball by UCLA," Staley said. "You can't help but to love up on it cause it was fluid on both sides of the ball." Given that it's only late November, the Gamecocks have plenty of time to figure things out. "We had some really good contributions from people that don't play a whole lot and we could probably give a little bit more minutes to," Staley said. "Taking a loss will help us focus on anybody that we play." Get local news delivered to your inbox!UMBC defeats Morgan State 92-69

CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. RLAY , a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that updated clinical data for RLY-2608 600mg BID + fulvestrant in patients with PI3Kα-mutated, HR+, HER2- locally advanced or metastatic breast cancer will be presented at the upcoming San Antonio Breast Cancer Symposium, taking place December 10-13, 2024. Details of the RLY-2608 + fulvestrant poster presentation are as follows: Abstract Title : PS7-01: Efficacy of RLY-2608, a mutant-selective PI3Kα inhibitor in patients with PIK3CA-mutant HR+HER2- advanced breast cancer: ReDiscover trial Abstract Number: SESS-2211 Session : Concurrent Poster Spotlight Session 7: Targeting the ER and PI3K pathway: Novel drugs and combinations Date/Time : Wednesday, December 11, 8:00-9:30 a.m. ET (7:00-8:30 a.m. CT) Conference Call Information Relay Therapeutics will host a conference call to discuss these data on Wednesday, December 11, 2024 at 7:00 a.m. ET (6:00 a.m. CT). Registration and dial-in for the conference call and webcast may be accessed through Relay Therapeutics' website under Events in the News & Events section through the following link: https://ir.relaytx.com/news-events/events-presentations . An archived replay of the webcast will be available following the event. The poster will be available at the start of the session on the company's website at https://relaytx.com/publications/ . About RLY-2608 RLY-2608 is the lead program in Relay Therapeutics' efforts to discover and develop mutant selective inhibitors of PI3Kα, the most frequently mutated kinase in all cancers, with oncogenic mutations detected in about 14% of patients with solid tumors. RLY-2608 has the potential, if approved, to address more than 300,000 patients per year in the United States, one of the largest patient populations for a precision oncology medicine. Traditionally, the development of PI3Kα inhibitors has focused on the active, or orthosteric, site. The therapeutic index of orthosteric inhibitors is limited by the lack of clinically meaningful selectivity for mutant versus wild-type (WT) PI3Kα and off-isoform activity. Toxicity related to inhibition of WT PI3Kα and other PI3K isoforms results in sub-optimal inhibition of mutant PI3Kα with reductions in dose intensity and frequent discontinuation. The Dynamo® platform enabled the discovery of RLY-2608, the first known allosteric, pan-mutant, and isoform-selective PI3Kα inhibitor, designed to overcome these limitations. Relay Therapeutics solved the full-length cryo-EM structure of PI3Kα, performed computational long time-scale molecular dynamic simulations to elucidate conformational differences between WT and mutant PI3Kα, and leveraged these insights to support the design of RLY-2608. RLY-2608 is currently being evaluated in a first-in-human trial designed to treat patients with advanced solid tumors with a PIK3CA (PI3Kα) mutation. For more information on RLY-2608, please visit here . About Relay Therapeutics Relay Therapeutics is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of complementary techniques and technologies, Relay Therapeutics aims to push the boundaries of what's possible in drug discovery. Its Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics' initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit www.relaytx.com or follow us on Twitter . Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding Relay Therapeutics' strategy, business plans and focus; the progress and timing of the clinical development of the programs across Relay Therapeutics' portfolio; the expected therapeutic benefits and potential efficacy and tolerability of RLY-2608, both as a monotherapy and in combination with other agents, and its other programs, including lirafugratinib as well as the clinical data for RLY-2608; the interactions with regulatory authorities and any related approvals; the potential market opportunity for RLY-2608; the cash runway projection and the expectations regarding Relay Therapeutics' use of capital, expenses and potential cost savings. The words "may," "might," "will," "could," "would," "should," "plan," "anticipate," "intend," "believe," "expect," "estimate," "seek," "predict," "future," "project," "potential," "continue," "target" and similar words or expressions, or the negative thereof, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: the impact of global economic uncertainty, geopolitical instability and conflicts, or public health epidemics or outbreaks of an infectious disease on countries or regions in which Relay Therapeutics has operations or does business, as well as on the timing and anticipated results of its clinical trials, strategy, future operations and profitability; the delay or pause of any current or planned clinical trials or the development of Relay Therapeutics' drug candidates; the risk that the preliminary or interim results of its preclinical or clinical trials may not be predictive of future or final results in connection with future clinical trials of its product candidates and that interim and early clinical data may change as more patient data become available and are subject to audit and verification procedures; Relay Therapeutics' ability to successfully demonstrate the safety and efficacy of its drug candidates; the timing and outcome of its planned interactions with regulatory authorities; and obtaining, maintaining and protecting its intellectual property. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in Relay Therapeutics' most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Relay Therapeutics' views only as of today and should not be relied upon as representing its views as of any subsequent date. Relay Therapeutics explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Contact: Megan Goulart 617-322-0814 mgoulart@relaytx.com Media : Dan Budwick 1AB 973-271-6085 dan@1abmedia.com © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.None

The green energy revolution is transforming even unlikely states despite political divisions, Bloomberg Opinion columnist Mark Gongloff writes. Click to share on Facebook (Opens in new window) Click to share on X (Opens in new window) Most Popular Chinese student’s drone got stuck in tree near Newport News Shipbuilding, leading to Espionage Act prosecution Chinese student’s drone got stuck in tree near Newport News Shipbuilding, leading to Espionage Act prosecution Former U.S. President Jimmy Carter dies at 100 Former U.S. President Jimmy Carter dies at 100 Candidates who ran against Sen. Christie New Craig say they tried to investigate residency concerns Candidates who ran against Sen. Christie New Craig say they tried to investigate residency concerns Longtime Phoebus Auction Gallery to close after New Year’s Day event Longtime Phoebus Auction Gallery to close after New Year’s Day event Column: Visiting America’s battlefields? Show some respect Column: Visiting America’s battlefields? Show some respect James City County officer, 17-year-old injured in Christmas Eve crash James City County officer, 17-year-old injured in Christmas Eve crash Norfolk State coach Michael Vick gains commitment from former UTSA defensive lineman Norfolk State coach Michael Vick gains commitment from former UTSA defensive lineman Journey of self: Williamsburg-area massage therapist helps others heal Journey of self: Williamsburg-area massage therapist helps others heal Column: Democrats take aim at Virginia’s marriage amendment Column: Democrats take aim at Virginia’s marriage amendment Juvenile humpback whale washes ashore on Outer Banks Juvenile humpback whale washes ashore on Outer Banks Trending Nationally Body found in wheel well of plane from Chicago to Maui How Diddy and Luigi Mangione spent Christmas in Brooklyn jail Massive invasive python is freed into the Palm Beach County wilderness. Here’s why ‘Baby Driver’ actor Hudson Meek dead at 16 Pregnant woman stabbed multiple times by pizza deliverer disgruntled about tip, sheriff says

NEW YORK (AP) — A slide for market superstar Nvidia on Monday knocked Wall Street off its big rally and helped drag U.S. stock indexes down from their records. The S&P 500 fell 0.6%, coming off its 57th all-time high of the year so far. The Dow Jones Industrial Average dipped 240 points, or 0.5%, and the Nasdaq composite pulled back 0.6% from its own record.NEW YORK (AP) — A slide for market superstar Nvidia helped pull U.S. stock indexes down from their records. The S&P 500 fell 0.6% Monday, coming off its 57th all-time high of the year so far. The Dow Jones Industrial Average fell 0.5%, and the Nasdaq composite dropped 0.6% from its own record. Nvidia was the market’s heaviest weight after China said it’s probing the chip giant for potential antitrust violations. Stocks in Hong Kong jumped after top Chinese leaders agreed on a “moderately loose” monetary policy. Prices for oil and gold rose following the ouster of Syrian leader Bashar Assad. THIS IS A BREAKING NEWS UPDATE. AP’s earlier story follows below. NEW YORK (AP) — A slide for market superstar Nvidia on Monday is helping to pull U.S. stock indexes down from their records. The S&P 500 fell by 0.3% in afternoon trading, coming off its 57th all-time high of the year so far. The Dow Jones Industrial Average was down 57 points, or 0.1%, as of 1:53 p.m. Eastern time, and the Nasdaq composite pulled back 0.3% from its own record. Nvidia's drop of 2.1% was by far the heaviest weight on the S&P 500 after China said it's investigating the company over suspected violations of Chinese anti-monopoly laws. Nvidia has skyrocketed to become one of Wall Street’s most valuable companies because its chips are driving much of the world’s move into artificial-intelligence technology. That gives its stock’s movements more sway on the S&P 500 than nearly every other. Nvidia's fall overshadowed gains in Hong Kong and for Chinese stocks trading in the United States on hopes that China will deliver more stimulus for the world's second-largest economy. Roughly half the stocks in the S&P 500 also rose. The week’s highlight for Wall Street will arrive midweek when the latest updates on inflation arrive. Economists expect Wednesday’s report to show the inflation that U.S. consumers are feeling remained stuck at roughly the same level last month. A separate report on Thursday, meanwhile, could show an acceleration in inflation at the wholesale level. They’re the last big pieces of data the Federal Reserve will get before its meeting next week on interest rates. The widespread expectation is still that the central bank will cut its main interest rate for the third time this year. The Fed has been easing its main interest rate from a two-decade high since September to offer more help for the slowing job market, after bringing inflation nearly all the way down to its 2% target. Lower interest rates can ease the brakes off the economy, but they can also offer more fuel for inflation. Expectations for a series of cuts from the Fed have been a major reason the S&P 500 has set so many all-time highs this year. On Wall Street, Interpublic Group rose 5.8% after rival Omnicom said it would buy the marketing and communications firm in an all-stock deal. The pair had a combined revenue of $25.6 billion last year. Omnicom, meanwhile, sank 9.3%. Macy’s climbed 1.5% after an activist investor, Barington Capital Group, called on the retailer to buy back at least $2 billion of its own stock over the next three years and make other moves to help boost its stock price. Super Micro Computer rose 4.6% after saying it got an extension that will keep its stock listed on the Nasdaq through Feb. 25, as it works to file its delayed annual report and other required financial statements. Earlier this month, the maker of servers used in artificial-intelligence technology said an investigation found no evidence of misconduct by its management or by the company’s board following the resignation of its public auditor . In the oil market, a barrel of benchmark U.S. crude rallied 2% to $68.56 following the overthrow of Syrian leader Bashar Assad, who sought asylum in Moscow after rebels. Brent crude, the international standard, was mostly unchanged at $71.05. The price of gold also rose 1% amid the uncertainty created by the end of the Assad family’s 50 years of iron rule. In stock markets abroad, the Hang Seng jumped 2.8% in Hong Kong after top Chinese leaders agreed on a “moderately loose” monetary policy for the world’s second-largest economy. That’s a shift away from a more cautious, “prudent” stance for the first time in 10 years. A major planning meeting later this week could also bring more stimulus for the Chinese economy. U.S.-listed stocks of several Chinese companies climbed, such as a 13.1% jump for electric-vehicle company Nio and a 9.1% rise for Alibaba Group. Stocks in Shanghai, though, were roughly flat. In Seoul, South Korea’s Kospi slumped 2.8% as the fallout continues from President Yoon Suk Yeol 's brief declaration of martial law last week in the midst of a budget dispute. In the bond market, the yield on the 10-year Treasury rose to 4.19% from 4.15% late Friday. ___ AP Business Writers Matt Ott and Elaine Kurtenbach contributed. Stan Choe, The Associated Press